摘要
Osteoporosis, which typically affects postmenopausal women, is an osteolytic disease due to over-activation of osteoclasts. However, current drugs targeting osteoclast inhibition face various side effects, making natural compounds with great interest as alternative treatment options. Cycloastragenol (CAG) is a triterpenoid with multiple biological activities. Previously, CAG's activity against aging-related osteoporosis was reported, but the mechanisms of actions for the activities were not understood. This study demonstrated that CAG dose-dependently inhibited osteoclast formation in receptor activator of nuclear factor-kappa B ligand (RANKL)-stimulated bone marrow macrophage (BMMs). Mechanism studies showed that CAG inhibited NF-kappa B, calcium, and nuclear factor of activated T cells 1 (NFATc1) pathways. Additionally, CAG also promoted the nuclear factor-erythroid 2-related factor 2 (Nrf2)/Kelch-like ECH-associated protein 1 (Keap1)/anti-oxidative response element (ARE) pathway that scavenges reactive oxygen species (ROS). Furthermore, CAG was also found to prevent bone loss of postmenopausal osteoporosis (PMO) in a preclinical model of ovariectomized (OVX) mice. Collectively, our research confirms that CAG inhibits the formation and function of osteoclasts by regulating RANKL-induced intracellular signaling pathways, which may represent a promising alternative for the therapy of osteoclast-related disease.
学科与关键词
- Kirenol inhibits RANKL-induced osteoclastogenesis and prevents ovariectomized-induced osteoporosis via suppressing the Ca2+-NFATc1 and Cav-1 signaling pathwaysZou, Binhua; Zheng, Jiehuang; Deng, Wende; Tan, Yanhui; Jie, Ligang; Qu, Yuan; Yang, Qin; Ke, Minhong; Ding, Zongbao; Chen, Yan; Yu, Qinghong*; Li, Xiaojuan*PHYTOMEDICINE, 2021, 80: 153377.被引 20
- Asiatic Acid Inhibits OVX-Induced Osteoporosis and Osteoclastogenesis Via Regulating RANKL-Mediated NF-κb and Nfatc1 Signaling PathwaysHong, Guoju; Zhou, Lin; Han, Xiaorui; Sun, Ping; Chen, Zhenqiu; He, Wei; Tickner, Jennifer; Chen, Leilei*; Shi, Xuguang*; Xu, Jiake*Frontiers in Pharmacology, 2020, 11: 331.被引 19
- A novel RANKL-targeted flavonoid glycoside prevents osteoporosis through inhibiting NFATc1 and reactive oxygen speciesHong, Guoju; Chen, Zhenqiu; Han, Xiaorui; Zhou, Lin; Pang, Fengxiang; Wu, Rishana; Shen, Yingshan; He, Xiaoming; Hong, Zhinan; Li, Ziqi; He, Wei; Wei, Qiushi*Clinical and Translational Medicine, 2021, 11(5): e392.被引 31
